This activity has expired. Credit is no longer available.
Supported by an educational grant from Puma Biotechnology.

Advances in Extended Adjuvant HER2-Positive Early Breast Cancer

G. Thomas Budd, MD
Taussig Cancer Center at Cleveland Clinic

Wendy H. Vogel, MSN. FNP, AOCNP®
Wellmont Cancer Institute

Examine the mechanisms of action of extended adjuvant therapies for HER2-positive early breast cancer, in addition to strategies for combating patients’ side effects and the latest guidelines on HER2 testing. Advanced practitioners can also learn about their critical role in properly selecting patients for treatment, educating them about their treatment options, and managing treatment adherence.


Download Transcript


Download Slides


These activities, certified for CME/CE/CPE credit, are jointly provided by

Annenberg Logo Harborside Press Logo
Copyright © 2010-2019 Harborside Press, LLC All rights reserved.               
Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact | Copyright Notice/Disclaimer | Subscribe
Bot trap - Don't go here
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.